AtriCure (NASDAQ:ATRC) Insider Karl Dahlquist Sells 9,370 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Karl Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

AtriCure Stock Performance

AtriCure stock opened at $48.17 on Thursday. The stock has a 50-day simple moving average of $37.09 and a 200 day simple moving average of $32.06. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $49.88. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of 229.39 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter last year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts anticipate that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ATRC. Bank of America Corp DE grew its holdings in AtriCure by 13.7% during the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after purchasing an additional 92,830 shares during the period. Assenagon Asset Management S.A. acquired a new stake in AtriCure in the second quarter worth $1,744,000. Rice Hall James & Associates LLC acquired a new stake in AtriCure in the second quarter worth $3,755,000. F m Investments LLC bought a new position in shares of AtriCure during the fourth quarter worth $2,872,000. Finally, Vanguard Group Inc. grew its holdings in shares of AtriCure by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after buying an additional 62,861 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ATRC. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday. UBS Group decreased their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.62.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.